Japanese medtech firm Terumo establishes corporate venture capital to support innovation

Japan-based Terumo Corporation has established Terumo Ventures, a Corporate Venture Capital (CVC) organisation responsible for leading the Group's venture investments, as a department within Terumo Americas Holding, Inc.

Terumo Ventures operates in global innovation hubs around the world, such as Massachusetts and California in the United States, and invests $75 million over the next five years in early-stage companies primarily in the fields of cardiovascular disease treatment, chronic disease treatment, and digital technologies. This will enable Terumo to enhance its access to innovative technologies and business ideas from startups, promote open innovation, and pursue synergies with its internal R&D efforts.

Terumo has been building relationships with medtech startups by investing in venture capital funds in the United States and China since 2013.

With the establishment of the CVC, the company will further increase its agility in identifying, evaluating, and executing venture investments, while accelerating the speed of acquiring cutting-edge technologies and developing a robust M&A target pipeline for future growth.

The company has been working to strengthen its innovation capabilities. This includes the introduction of the new director position in charge of innovation in April 2024. Going forward, Terumo will continue to enhance its ability to create innovation through a combination of internal development and partnerships with external parties to further expand the value it provides to society.